AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 95 min read$ANGO

AngioDynamics (ANGO) Q1 2027 Earnings Call Transcript

AngioDynamics (ANGO) reported Q1 2027 revenue growth of 7%, with the MedTech segment up 13%. Auryon saw 14.7% growth, marking 21 consecutive quarters of double-digit gains. AlphaVac revenue rose 37.4% year-over-year. The company named Eric Honer as its new CEO, effective November 2. NanoKnife received FDA approval for a BPH study, targeting a $1.9B market. Med Device segment grew 1.4%.

Original reporting
finance.yahoo.com
Published Oct 9, 2026, 2:43 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 9, 2026, 3:07 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AngioDynamics (ANGO) Q1 2027 Earnings Call Transcript — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$ANGOBullishHigh
01

Why it matters

The earnings beat and leadership change provide fresh data for traders to reassess valuation and short-term price direction.

02

Market read

First release of FY27 Q1 numbers and CEO appointment creates immediate trading relevance for ANGO and may influence medtech peers.

03

What to watch

Potential integration challenges for the new CEO and the modest decline in AngioVac sales may temper upside.

Relevance 7/10Novelty 8/10Timing: post-earnings release today

Background

AngioDynamics held its FY27 Q1 earnings call, reporting $80.9M revenue, 13.2% medtech growth, FDA approval for NanoKnife relief study, and announced Eric Honer as new CEO effective Nov 2.

Company-level read

Ticker impact

$ANGOBullishHigh confidence
Context

Q1 FY27 earnings released with revenue up 6.9% to $80.9M, medtech revenue up 13.2%, and appointment of new CEO Eric Honer effective Nov 2.

Expected impact

potential upside as investors price in earnings beat and new CEO outlook

Evidence & confidence

Revenue growth exceeds prior year and the new CEO brings extensive medtech experience, likely boosting confidence.

Market effects

Sector

Medtech segment growth may lift peer medtech stocks and reinforce sector momentum.

Regional

U.S. medtech market sees incremental demand from AngioDynamics' product launches.

Global

Limited to U.S. investors; no immediate global ripple.

Counterpoint

What could challenge this read

If earnings expectations were already high, the modest revenue increase could be seen as a miss, pressuring the stock.

Key entities

  • Company
    AngioDynamics

    Medical device manufacturer reporting FY27 Q1 results.

  • Executive
    Eric Honer

    New President and CEO effective November 2.

  • Executive
    Stephen A. Trowbridge

    EVP and CFO presenting the financial results.

Read at source← All news

StoryAngioDynamics reports Q1 FY2027 earnings beat and names new CEO Eric Honroth

Also covered by

5 outlets

Related articles

OCT 8
$ANGOHighAI 8/10

AngioDynamics, Inc. Q1 2027 Earnings Call Summary

AngioDynamics reported Q1 2027 earnings, with MedTech segment revenue growing 13.2% YoY, now 49% of total revenue. Auryon saw 21st straight quarter of double-digit growth. NanoKnife adoption increased, with record procedure volumes. Full-year revenue guidance is $336M-$341M, with MedTech expected to dominate. Gross margin expanded 410 bps due to pricing and mix shift. Eric Honer appointed as new CEO. The company remains debt-free and expects positive cash flow for the year.

finance.yahoo.com3 min
OCT 8
$ANGOHigh

Why AngioDynamics Crashed Today

AngioDynamics (ANGO) shares fell 20.7% despite beating Q1 earnings estimates. The company reported a $0.04 per share pro forma loss, but a $0.17 GAAP loss. Revenue grew 6.9% year-over-year. Eric Honroth was named CEO, succeeding Jim Clemmer. The company has not been profitable since 2020 and is not expected to be until 2029, according to analysts.

finance.yahoo.com2 min
OCT 8
$ANGOMed

AngioDynamics Q1 Earnings Call Highlights

AngioDynamics (ANGO) reported Q1 revenue growth in NanoKnife, up 29% to $8.3M, with probe sales rising 24.1% and capital sales up 53.5%. The company expects AlphaReturn to expand its product line. Gross margin improved to 59.4%, and adjusted EBITDA increased to $5M. The company reaffirmed its fiscal 2027 outlook, expecting revenue of $336M-$341M and adjusted EBITDA of $13M-$16M.

finance.yahoo.com2 min